Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 43Colorectal Neoplasms 32Stomach Neoplasms 28Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Head and Neck Neoplasms 12Advanced Solid Tumor 12Cholangiocarcinoma 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease × tislelizumab × Clear all
NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Anbogen Therapeutics, Inc.

Phase 1/2 Recruiting
66 enrolled
Gastrointestinal

Disease, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡